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This study describes two analytical methods, by second-order derivative UV spectrophotometric by HPLC, for determination of 
vildagliptin, a drug used for treatment of type 2 Diabetes Mellitus that belongs to a therapeutic class called inhibitors of dipeptidyl 
peptidase 4. The methods were validated in accordance with ICH and USP requirements. Analyses by UV derivative method were 
performed at 220 nm, which was the zero crossing point of excipient solutions. HPLC was optimized and the analysis was carried 
out using a Zorbax Eclipse Plus RP-C8 column (150 mm × 4.6 mm, 5 μm), detection at 207 nm, and potassium phosphate buffer 
solution pH 7.0 : acetonitrile (85:15, v/v) as mobile phase. In dissolution test, the conditions used were 0.01 mol L
-1
 hydrochloric 
acid in 900 mL of dissolution medium, USP apparatus 2 (paddle) and 50 rpm stirring speed. Both methods were successfully 
applied for analysis of dissolution samples from marketed vildagliptin tablets.  
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Introduction  
 
Diabetes mellitus is a progressive disease 
characterized by deterioration of pancreatic islet 
cell function and increased insulin resistance (1). 
It is a disease of multiple etiologies that affects 
quality of life of affected individuals (2). 
Inhibitors of dipeptidyl peptidase-4 (DPP-
4) represent a new class of antidiabetic agents for 
the treatment of type 2 diabetes, which improves 
glycemic control by preventing the degradation of 
intestinal peptides, also known as incretins. In 
order to improve glycemic control and slowing 
disease progression, pharmacological and non-
pharmacological alternatives have been 
developed. In relation to pharmacological 
intervention, the treatment with DPP-4 inhibitors 
have been considered (3,4).  
Vildagliptin (VLG), (S)-1-[N-(3-hydroxy-
1-adamantyl) glycyl] pyrrolidine-2-carbonitrile 
(Figure 1), is a potent and selective dipeptidyl 
peptidase-4 (DPP-4) inhibitor that improves 
glycemic control in patients with type 2 diabetes 
mellitus by increasing α- and β-cell 
responsiveness to glucose. It was approved in 
Europe as a complementary therapy to metformin, 
sulfonylurea and thiazolidinone (5).  
Drug dissolution testing is known as an 
integral part used by pharmaceutical industry to 
guide in product development and quality control 
routine in order to monitor drug release 
characteristics (6). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical Structure of Vildagliptin. 
 
As well as dissolution testing is essential to 
evaluate drug product performance, to assess 
batch-to-batch quality, to ensure continuing 
product quality and performance after certain 
changes, such as changes in the formulation or in 
the manufacturing process, the method validation 
is important and essential to ensure that the 
analytical method that will be used to analyze the 
dissolution media at different time points and 
quantify the amount of substance released is fit for 
its purpose (7,8). 
Once technological and scientific progress 
has led to the development of numerous synthetic 
drugs, it is imperative to develop analytical 
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methods to determine these drugs in the quality 
control manufacturing phase of the 
pharmaceutical formulations. For this purpose, 
several analytical methods, including derivative 
spectrophotometry in the UV region have been 
used as a tool for quantitative analysis and quality 
control in pharmaceutical analysis. UV derivative 
spectrophotometry is an analytical technique of 
great utility for extracting both qualitative and 
quantitative information from overlapping bands 
of the analytes and interferences. The common 
availability of the instrumentation, the simplicity 
of procedures, speed, precision and accuracy of 
the technique still make spectrophotometric 
methods attractive (9-13). 
In the literature, there were found some 
methods by using HPLC-UV for VLG 
quantitation in association with other drugs or 
alone (14-19) and by UV spectrophotometry based 
on chemical derivatization methods also for 
vildagliptin quantitation in pharmaceutical 
formulations (20,21). However, the 
chromatographic and spectrophotometric methods 
available were used for different purposes. Since 
there is no work related to evaluation of 
vildagliptin dissolution in tablets and no analytical 
methods were reported for this focus, the aim of 
this work was to develop and validate a 
discriminative dissolution method employing two 
analytical methods to determine vildagliptin by 
high-performance liquid chromatography (HPLC) 
and by second-order derivative UV 
spectrophotometry (2D-UV). 
 
Experimental 
 
Material 
 
The reference standard for VLG (purity of 
99.5%) was purchased of Sequoia Researched 
Products (United Kingdom) and the commercial 
tablets containing 50 mg of VLG (Galvus
®
, 
Novartis Biociências S. A., SP, Brazil) were 
obtained from commercial sources within their 
shelf life period. The reference and sample 
solutions were filtered through a 0.45 μm 
membrane filter (Millipore, Bedford, USA). 
Purified water was obtained by a Millipore
®
 
Direct-Q 3UV with pump (Molsheim, AL, 
France). All the other reagents were of analytical 
grade and buffer solutions were prepared 
according to USP 34 (22). 
 
2D-UV Instrumentation 
 
UV-Vis UV-1800 double-beam 
spectrophotometer (Shimadzu, Kyoto, Japan) with 
1 cm quartz cells was employed. UVProbe 2.33 
software was used for instrument control and data 
acquisition. The second-order derivative spectra of 
solutions were recorded at a fast scan speed with a 
fixed slit to lead to a spectral resolution of 1 nm. 
The spectra were obtained by instrumental 
electronic differentiation using a wavelength 
interval (Δλ) of 8 nm in the range of 200–300 nm. 
The determinations were made at 220 nm. All 
analytical responses obtained were multiplied by 
20 (scaling factor of 20). The spectrophotometric 
measurements were recorded by using water as a 
blank solution. 
 
HPLC Instrumentation 
 
  Liquid chromatography (LC) method was 
carried out in a liquid chromatography (LC) 
Shimadzu 20-A system equipped with a CBM-
20A system controller, LC-20AT pump, SIL-
20A/C auto sampler, CTO-20A/C column oven 
and SPD-M2OA PDA detector. The experiments 
were performed on an analytical column Zorbax 
Eclipse Plus RP-C8 (150 mm x 4.6 mm, 5 µm). 
The LC system was operated isocratically at 25 °C 
in the column oven, using a mobile-phase 
composed by a solution of 50 mM potassium 
phosphate buffer and acetonitrile (85:15 v/v), at a 
flow-rate of 1.0 ml min
-1
, using detection at 207 
nm. The pH of mobile phase was adjusted at 7.0 
using phosphoric acid in the aqueous phase and, 
then, it was done the mixture of both aqueous and 
organic phases. The injection volume was 20 μL. 
The peak areas were integrated automatically by 
computer using LC-Solution manager system 
software. 
 
Dissolution performance 
 
 Dissolution test was performed in a 
Vankel
®
 VK 7010 multi-bath (n=8), auto-
sampling consisting of a bidirectional peristaltic 
pump. Vildagliptin 50 mg tablets were dissolved 
in 900 mL of 0.01 mol L
-1
 HCl at 37 °C using 
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paddles. The collected samples were filtered 
through 0.45 μm membrane filter. 
 
Solutions 
Preparation of reference and sample solutions 
 Stock solution was prepared by weighing 
accurately 25 mg of VLG reference substance, 
transferred to individual 25 mL volumetric flask 
and diluted to volume with water, obtaining the 
concentration of 1.0 mg mL
-1
. The stock solution 
was stored at 2–8 °C, protected from light and 
diluted to a final concentration of 50 μg mL–1 and 
100 µg mL
-1
 (working solution) for HPLC and 
2D-UV determinations, respectively. 
 The tablets containing 50 mg of VLG were 
accurately weighed and crushed to fine powder. 
An appropriate amount was transferred into an 
individual 25 mL volumetric flask, diluted to 
volume with water, sonicated for 10 min and 
filtered through a filter paper, obtaining the 
concentration of 1.0 mg mL
-1
 of VLG. This stock 
solution was stored at 2-8 °C and protected from 
light. Working sample solutions were prepared by 
diluting the stock solution to appropriate 
concentrations (50 and 100 µg mL
-1
 for HPLC and 
2D-UV, respectively) in purified water.  
 
Methods 
HPLC and 2D-UV Method Validation 
 
 The proposed methods were validated for 
drug specificity, linearity, precision, accuracy and 
robustness according with USP (22) and ICH (23) 
guidelines. Specificity was evaluated by 
interference of excipients from formulation. 
Linearity of three analytical curves were prepared 
with seven concentrations at ranges 25-175 µg 
mL
-1 
and 10-90 µg mL
-1
 of reference solution for 
2D-UV and HPLC, respectively. The results 
obtained were plotted against the respective drug 
concentrations to obtain the analytical curve. The 
precision was performed through six sample 
solutions, at the concentrations of 100 µg mL
-1
 
and 50 µg mL
-1
 to 2D-UV and HPLC, 
respectively. The relative standard deviation 
(RSD) was determined on three different days for 
intra-day and inter-day precisions. Accuracy was 
calculated in relation of the percentage of 
recovery by the assay of known added amount of 
vildagliptin reference solution using three 
concentration levels. The added levels were 25, 50 
and 75% of the nominal drug concentration. 
Robustness was evaluated by Plackett-Burman 
experimental design in order to detect potential 
sources of variability in the analytical methods in 
an interval that slightly exceeds the variations 
which can be expected when a method is 
transferred from one instrument to another or from 
one laboratory to another. 
 
Application of proposed methods  
Dissolution studies 
 
 The selection of the dissolution medium 
was made by considering the solubility of 
vildagliptin in order to ensure sink conditions. As 
the drug in study is highly water soluble, in all 
conditions tested the sink conditions were 
achieved. The dissolution profiles were performed 
at three different dissolution media, within the 
physiological pH range (7). The sink conditions 
were determined in different solvents: 0.01 mol L
-
1
 HCl, acetate buffer pH 4.5 and 5.0 and 
phosphate buffer pH 6.0, 6.8 and 7.4. For 
dissolution tests, 900 mL of each medium were 
deaerated, by stirring and heating, and maintained 
at 37 ± 0.5 ºC. USP apparatus, paddle and basket, 
were tested. For paddle apparatus stirring speeds 
of 50 and 75 rpm were tested and for basket 50 
and 75 rpm were tested. The test time was set on 
60 min. Aliquots of 5.0 mL were withdrawn from 
each vessel without replacement of dissolution 
medium. Later, calculations were performed for 
volume correction. The times selected were: 5; 10; 
15; 20; 30; 45 and 60 min. The samples were 
analyzed by derivative UV spectrophotometric 
method and HPLC method (n = 3).  
  
Results and discussion 
 
Analytical Method Validation 
2D-UV method  
Specificity  
 Spectrophotometric methods are more 
economic and simple compared to methods such 
as chromatography and electrophoresis, and can 
provide a very useful alternative for quality 
control of pharmaceutical formulations. 
Derivative spectra can be used to clarify 
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absorption bands in more complex UV spectra. In 
comparison with conventional spectrophotometric 
determinations, derivative spectrophotometry has 
proved to be of a great value in eliminating the 
interference from excipients and co-formulated 
drugs (13-16).  
 In order to evaluate specificity of the 2D-
UV method, placebo solutions were prepared and 
analyzed by zero-order UV spectrum showing 
strong and significant interference from the tablet 
excipients in all the region of VLG absorption 
spectrum, which prevent the analytical use of 
zero-order spectrophotometry (Figure 2a). The 
first derivative was also discarded due to lack of 
selectivity (Figure 2b). For this reason, the 2D-UV 
method was considered to be ideal for solving the 
overlapping of excipients absorption over VLG 
signal. As observed in Figure 2c, the zero-crossing 
for placebo solution appears at 220 nm, using a Δλ 
of 8 nm and 20 as scaling factor. Therefore, this 
value was selected as optimum to determine VLG 
in the presence of the pharmaceutical excipients.  
 
Figure 2. Zero-order absorption spectra (a), first-order derivative 
spectra (b) and second-order derivative spectra (c) of vildagliptin 
sample solution and placebo solution, in water at concentration of 
100 μg mL–1. 
 
Linearity 
 
 Linearity was observed over the 
concentration range of 25 to 175 µg mL
-1
 in 220 
nm with linearity equation y = 0.0015x + 0.0033 
(r
2
 = 0.9995), where x is the VLG concentration 
(expressed as µg mL
-1
) and y is the amplitude 
from the peak at 220 nm. The variance analysis (p 
= 0.05) was applied to verify the linearity of the 
method and the results showed that the regression 
equation was linear (Fcalculated = 60506.3 > 
Fcritical = 4.60) with no deviation from linearity 
(Fcalculated = 2.93 < Fcritical = 2.96). 
 
Precision 
 
 The experimental values obtained for the 
determination of the precision of analytical 
method are presented in Table 1. The low relative 
standard deviation (RSD) obtained for the 
repeatability and intermediary precision showed 
the precision of the method. 
 
Table 1. Inter-day and intraday precision data for vildagliptin in 
samples of pharmaceutical formulation obtained by UV derivative 
method at 220 nm. 
 
Sample (n) 
Repeatability Intermediate precision 
Day 1 Day 2 Day 3* 
1 97.97 99.86 97.78 
 
2 99.47 97.16 97.78 
3 97.78 97.99 96.51 
4 98.41 98.87 97.34 
5 97.78 96.91 97.97 
6 99.04 97.55 97.15 
Mean (%) 98.41 98.06 97.42 97.96 
RSD 0.72 1.14 0.55 0.88 
* Different analyst 
 
Accuracy  
 
 The accuracy of the method ranged 96.16 
to 98.95% (RSD = 1.45). The results are shown in 
Table 2. These values showed the accuracy of the 
purposed method. 
 
Table 2. Results of method accuracy for 2D-UV method applied to 
vildagliptin (VLG) in pharmaceutical formulation. 
Drug 
Added Level 
(µg mL-1) 
Total Nominal 
Concentration 
(µg mL-1) 
Mean 
Concentration 
founda 
(µg mL-1) 
Accuracy 
(%) 
RSDb 
(%) 
 
VLG 
25 (25%) 125.0 120.34 96.27 1.31 
50 (50%) 150.0 144.02 96.01 0.44 
75 (75%) 175.0 167.72 95.84 0.22 
aMean of three replicates   
bRSD = relative standard deviation 
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Robustness  
 
 The results of the robustness study are 
presented in Table 3. They are expressed in 
percentage of the drug in relation to the nominal 
dose, calculated using standard solution in the 
nominal condition of the method. 
 
Table 3. Responses (percentage of VLG in the commercial tablets 
relative to its label claimed concentration) obtained, in each assay, 
in relation to the standard solutions after changes in factors 
investigated by robustness test. 
 
The effects of the factors in analysis, the 
error estimated starting from the dummy factors 
and the value of t calculated are shown in Table 4. 
The analysis of the results from robustness study 
demonstrated that the factors did not present 
significant effect on the quantitation of VLG, 
indicating the robustness of the UV derivative 
spectrophotometric method. 
 
Table 4. Experimental values of the effects and t-calculated of the 
factors analyzed in the robustness testing for validation of 2D-UV 
method applied to vildagliptin (VLG) in pharmaceutical 
formulation. 
Factor |Effect| t-calculated 
Mechanically shaken 1.04 2.48a 
Shaken in ultrasonic bath 0.27 0.64a 
Wavelength of the detector 0.55 1.30a 
aNo statistical difference to t (0.05; 2); experimental error Ee = 0.420. 
 
HPLC method 
HPLC method here employed was based 
in a previously published paper (17), in which a 
HPLC method for the quantitation of VLG in 
pharmaceutical tablets was developed and 
validated. According to ICH, revalidation may be 
necessary in the circumstances that there are 
changes in the composition of the finished product 
and/or in the analytical procedure. Therefore, the 
original method suffered one modification in the 
mobile phase content because it was applied for a 
different purpose. In this study the main objective 
was to quantify VLG from tablets in a dissolution 
test. Hence, the method was revalidated to meet 
this new proposal. 
 
Specificity 
 
 The specificity was confirmed as the 
formulation excipients of the pharmaceutical 
tablet product did not interfere in the method 
determination at 207 nm (Figure 3), allowing 
reliable results. 
Figure 3. Vildagliptin sample solution chromatogram with placebo 
solution overlapping. 
 
Linearity 
 
 Three analytical curves constructed for 
vildagliptin were found to be linear in the 10–90 
µg mL
−1
 range. The value of the determination 
coefficient calculated (r
2
 = 0.9999, y = 18354x - 
3747.3) indicated the linearity of the analytical 
method. The validity of the assay was also 
verified by means of ANOVA, which 
demonstrated significant linear regression (p < 
0.05) and non-significant linearity deviation (p > 
0.05). 
 
Precision 
 
 Repeatability and intermediate precision 
were determined and the obtained results are 
illustrated in Table 5. All the data are within the 
acceptance criteria (RSD) of 2%, which indicate 
the method precision. 
Experiment 
Mechanically 
shaken (min) 
Ultrasonic 
bath (min) 
Wavelength 
(nm) 
Percentage of 
VLG (%) 
1 6 15 222 98.65 
2 6 6 218 98.88 
3 15 6 218 99.09 
4 15 15 218 96.69 
5 6 15 222 96.91 
6 15 6 222 97.69 
7 15 6 218 98.69 
8 6 15 222 97.91 
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Table 5. Results of intraday and interday precision for VLG tablets 
by HPLC method. 
 Day 1 (n=6) Day 2 (n=6) Day 3 (n=6) 
Average Intraday (%) 98.19 98.52 98.09 
RSD Intraday (%)  0.97 0.64 1.06 
Average Interday (n=18)  98.27  
RSD Interday (%)  0.87  
 
Accuracy 
  
 There were found excellent mean 
percentage recovery values. The mean recovery 
was 98.96% (RSD = 1.82%) for tablets. The 
results are presented in Table 6. At each level of 
VLG concentration, three determinations were 
performed. 
 
Table 6. Experimental values obtained in the recovery test for 
vildagliptin by using HPLC method. 
Added 
level 
(µg mL-1) 
Nominal 
concentration 
(µg mL-1) 
Mean 
concentration 
founda (µg mL-1) 
Accuracy 
(%) 
RSD (%) 
10 40 49.87 99.74  
20 40 58.98 98.30 0.89 
30 40 69.95 99.93  
a Mean of three replicates 
 
Robustness 
 
 Robustness was evaluated by small 
changes in the parameters like mobile phase 
composition and pH, column temperature and 
flow rate. In robustness studies, it was observed 
that the column temperature did not affect the 
drug elution. However, the mobile phase 
composition and flow rate resulted in changes in 
drug retention time but these small changes did 
not affect drug determination in the 
pharmaceutical formulations. 
 
Dissolution performance validation 
 
 Validation of dissolution performance was 
carried out by the two methods of quantification, 
2D-UV and HPLC. The concentration of 50 mg of 
vildagliptin in 900 mL of dissolution media is 
nearly equal to the central concentration (55 µg 
mL
-1
) at the established ranges. 
 Linearity was evaluated by three analytical 
curves of VLG standard in the dissolution media 
in range of 25-125 µg mL
-1
 (2D-UV method) and 
10-90 µg mL
-1
 (HPLC method). The high 
correlation coefficients calculated demonstrate the 
linearity of the proposed methods (Table 7). 
 
Table 7. Linearity results for dissolution studies of vildagliptin by 
2D-UV and HPLC. 
Parameters 2D-UV HPLC 
Linearity range (µg mL-1) 25 – 125 10 - 90 
Slope 0.0017 17884 
Intercept 0.0005 2115.3 
Correlation coefficient (r) 1.000 0.9999 
 
Precision was determined by crushing 
twenty coated tablets, containing 50 mg of drug, 
and checking their content by 2D-UV and HPLC 
instruments. Since this content is exactly known, 
the precision assay can be performed without the 
intrinsic variability of the tablets and dispensing 
the bulk and standard materials. The results for 
both validated methods were expressed as 
percentage of dissolution and RSD and are 
presented in Table 8. The RSD values were less 
than 2.0 % for repeatability and intermediate 
precision, indicating the precision of the 
dissolution method. 
 
Table 8. Results of precision for dissolution test applied to 
vildagliptin tablets. 
Samples 2D-UV Assay (%) 
HPLC Assay (%) 
 Day 1 Day 2 
Day 1 Day 2 
1 98.58 98.65 101.15 100.57 
2 99.39 98.02 99.35 100.28 
3 98.69 98.12 99.41 100.30 
Mean 98.89 98.26 
99.97 100.38 
RSD (%) 0.44 0.35 
1.02 0. 
Mean/RSD Interday (%): 98.58 / 0.50 
 
Mean/RSD Interday (%): 100.18 / 0.69 
 
Accuracy of the method was demonstrated 
by the recovery of known amounts of VLG in the 
dissolution vessels. Three levels were evaluated 
(low, medium and high). The results obtained and 
the mean recoveries are described in Table 9, 
which represent the accuracy of the methods.  
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Table 9. Recovery data for vildagliptin added to the dissolution 
vessels by using the proposed 2D-UV and HPLC methods. 
Method 
Levels 
(%) 
Added VLG 
(mg) 
Amount found 
(mg) 
Recovery 
(%) 
RSD 
(%) 
2D-UV 25 12.50 12.30 98.42 0.26 
 100 50.00 49.49 98.98 0.72 
 125 62.50 61.96 99.13 0.10 
HPLC 25 12.50 12.36 98.88 0.30 
 100 50.00 49.46 98.92 0.75 
 125 62.50 62.22 99.55 0.33 
 
  
 The drug release profile determined by the 
dissolution test conditions in Dissolution Studies 
Section (obtained for 2D-UV and HPLC method) 
is illustrated in Figure 4. The results are expressed 
as VLG concentration dissolved versus time. The 
obtained profiles were considered satisfactory 
once in conditions evaluated in another media by 
pH differences, apparatus and rotation speed the 
drug liberation occurred mainly in the first time 
points. The dissolution is quite fast, about 80% of 
the drug was dissolved within 10 min and the drug 
dissolution was concluded within 30 min. 
Figure 4. Dissolution profile of vildagliptin from tablets by CLAE and UV second 
derivative measurements. 
 
Comparation between 2D-UV and HPLC methods 
applied in dissolution test to vildagliptin in tablets 
 
 The validated 2D-UV spectrophotometric 
method was applied for the dissolution test of 
VLG in tablet dosage form and the results 
compared to those obtained using the HPLC 
method, as shown in Table 10. The experimental 
values of the two methods were compared 
statistically by ANOVA showing non-significant 
difference (p > 0.05). 
 
Table 10. Comparative determination applied for the dissolution 
test of vildagliptin in tablet dosage forms by 2D-UV and HPLC 
methods at 30 minutes. 
 
2D-UV method 
Experimental amount 
(mg/tablet) 
RSD 
(%) 
HPLC method 
Experimental amount 
(mg/tablet) 
RSD 
(%) 
Day 1* 49.31 0.05 50.43 0.41 
Day 2* 49.35 0.98 49.91 0.66 
Day 3* 49.20 0.41 49.93 0.63 
*Mean of six determinations 
 
Conclusions 
 
 A dissolution test for vildagliptin tablets 
determination was presented in this study. 2D-UV 
and HPLC analytical methods were validated and 
can be used to quantitation and evaluation of the 
release profile of vildagliptin in tablets. There is 
no significant difference between the validated 
HPLC and 2D-UV methods. It represents that 
both methods are useful for quantitative 
determination and dissolution evaluation of 
vildagliptin and can be applied in the laboratory 
routine analysis. 
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